Caffeine increases IOP and OPP in POAG

Article

Consuming one cup of caffeinated coffee statistically increases IOP and ocular perfusion pressure (OPP) in primary open-angle glaucoma (POAG) patients.

Consuming one cup of caffeinated coffee statistically increases IOP and ocular perfusion pressure (OPP) in primary open-angle glaucoma (POAG) patients. patients, claims a paper in Eye.

Dr A.Z. Jiwani et al., Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA, conducted a prospective, double-masked, crossover, randomized controlled trial on 106 subjects. Of these participants, 22 had high-tension POAG, 18 had normal tension, 21 POAG suspects and 25 healthy volunteers.

Each subject was given either 237 mL of caffeinated coffee or decaffeinated coffee at the first visit and the alternate beverage on the second visit. The outcome measures included blood pressure (BP) and pascal dynamic contour tonometer measurements of IOP ocular pulse amplitude (OPA) and heart rate. These were all measured before and at 60 and 90 minutes after coffee ingestion.

The results demonstrated no significant difference in baseline IOP, OPP and OPA between caffeinated and decaffeinated drinks. Mean mmHg changes in IOP, OPP and OPA were 0.99, 1.57 and 0.23, at 60 minutes, respectively. The results at 90 minutes for IOP, OPP and OPA were and 1.06, 1.26 and 0.18, respectively.

This suggests that consuming one cup of caffeinated coffee statistically increases but is not likely to clinically impact IOP and OPP in POAG cases.

The abstract can be found here .

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.